中国癌症防治杂志2025，Vol.17Issue(6)：739-746,8.DOI:10.3969/j.issn.1674-5671.2025.06.12
抗体偶联药物在非小细胞肺癌联合治疗中的临床实践与挑战
Clinical practice and challenges of antibody-drug conjugate in combination therapy for non-small cell lung cancer
摘要
Abstract
Antibody-drug conjugate(ADC)facilitate precise targeting of non-small cell lung cancer(NSCLC)by delivering potent cytotoxic agents directly to tumor cells,but monotherapy with ADC limited by tumor heterogeneity and acquired resistance.In recent years,combination therapy strategies that integrate ADC with immune checkpoint inhibitors and targeted agents have demonstrated superior efficacy in driver gene-negative NSCLC.This approach not only offers a chemotherapy-sparing treatment model,but also significantly transforms the therapeutic landscape for advanced NSCLC.This review aims to systematically summarize the biological mechanisms and the latest clinical advances of ADC-based combination therapy,while also exploring key challenges and future directions.It seeks to provide a theoretical foundation and clinical practical insights for precision treatment in advanced NSCLC.关键词
非小细胞肺癌/抗体偶联药物/联合治疗/精准医学Key words
Non-small cell lung cancer/Antibody-drug conjugate/Combination therapy/Precision medicine分类
医药卫生引用本文复制引用
张业然,谭元元,许雅丽..抗体偶联药物在非小细胞肺癌联合治疗中的临床实践与挑战[J].中国癌症防治杂志,2025,17(6):739-746,8.基金项目
山东省自然科学基金联合基金项目(ZR2022LSW001) （ZR2022LSW001）
